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with this integrated approach,10 detailed evaluation in larger
randomized multicenter studies is warranted to document
long-term effectiveness of hybrid revascularization compared
with conventional coronary artery bypass grafting or inter-
ventional therapy alone.
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Mechanical mitral valves without long-term antico-
agulation up to thirteen years
To the Editor:
If a mechanical valve could be left without anticoagulation,
a continuous risk factor for severe bleeding, with an inci-
dence of around 1% every year, could be avoided.
Ordinary Björk-Shiley Monostrut heart valves (Shiley, Inc,
Irvine, Calif) were inserted in the mitral position in goats.
After 1 year without anticoagulation, we found no instances
of thrombosis on the pyrolytic discs or on the metal struts, but
the suture rings in all cases were covered by an endothelial-
ized layer of thrombus. From this layer a thrombus did pro-
trude into the valve orifice in 8 of 9 goats.
The solution was to catch the covering from the suture ring
and have it endothelialized and firmly fixed to the metal ring.1
It was possible to sinter small, 20 to 30 m m round pearls of the
same metal to the metal ring of the valves at high temperature
in 3 layers. This enables roots to develop between the pearls
so that the covering will not come loose. An endothelialized
covering always developed on microporous surfaced rings tied
into the superior vena cava in goats.2 With 100 m m pearls the
vascular covering was too thick.2
In 1984 we started to implant the microporous surfaced
mitral valve in goats. After 21⁄2 months without anticoagulation,
the microporous area showed a homogeneous endothelialized
surface with nutrition direct from the blood so that it stayed
thin for more than 5 years.3 The continuous covering from the
suture ring went over the groove down in the valve, and after 5
years without anticoagulation the valve was still nicely covered
and the goats produced offspring without problems.3
The pilot study. This microporous surfaced mitral valve
prosthesis has the same strength as the Björk-Shiley
Monostrut valve,4 which has been implanted in about 140,000
patients during a 17-year period without any mechanical fail-
ures. We operated on a small group of 12 patients 11 and 13
years ago.5 All these patients had sinus rhythm. There were 5
children aged 7 to 15 years with mitral insufficiency and car-
diomegaly.5 Patient 10 was cachectic and needed enteral nutri-
tion for weeks before the operation. An 8-year-old boy (case
9) had a severe form of sickle cell anemia, with a hemoglobin
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Fig 1. The microporous surfaced 25 mm mitral Björk-Shiley
Monostrut heart valve after 21⁄2 years without anticoagulation in
a goat. The valve is viewed from the left ventricle with the disc
in the open position. The carbon-coated Teflon suture ring is
covered with thin, smooth, glistening yellow endothelium
extending over the groove and adjacent part of the valve flange.
S value of 95%, and required exchange transfusion before the
operation. He died 3.8 years after the operation of a sickle cell
crisis with joint hemorrhage. The valve was normal at autop-
sy. The second death (patient 12) occurred 4.4 years after the
operation from the rupture of a mycotic cerebral aneurysm.
The valve sounds were normal.
The entire surface was microporous in the 3 first patients
(1, 2, and 3). In all others (patients 4-12) the contact area
between the disc and the struts was polished. As soon as the
chest tubes were removed, heparin was given together with
warfarin until an effective level was reached. The heparin was
then discontinued and the warfarin continued for 3 months,
that is, until the endothelialization of the microporous surface
was complete. The patient then remained in the hospital for 7
days during subcutaneous heparin treatment after warfarin
was withdrawn. No anticoagulant has been given since for 11
to 13 years.
Cardiologists have performed the follow-up every third
month for those living close to the hospital and once a year
for the others. A Doppler echocardiogram (including trans-
esophageal echocardiography) was performed in July 1995.
The last clinical and echocardiographic follow-up examina-
tion was in the fall of 1998.
Results. Not a single thromboembolic complication has
been observed. Transesophageal echocardiographic Doppler
investigation performed during the summer of 1995 did not
show any thrombi. During the follow-up period, 9 pregnan-
cies occurred. All surviving patients were followed up dur-
ing the fall of 1998. Only patient 1 did not come to the clinic
but was contacted by telephone. No thromboembolic episode
had occurred. Patients 6 and 10 were in New York Heart
Association class II and the remaining 8 patients were in
class I. Patients 6 and 10 had moderate tricuspid regurgita-
tion and patient 10 also moderate aortic regurgitation. No
one else had any other significant native valvular dysfunc-
tion. All 10 survivors were in sinus rhythm and had normal
kidney function. The follow-up results are summarized in
Tables I and II.
Discussion. For mitral valves the whole metal surface area
can be microporous, as it was in the first 3 patients. It is, how-
768 Letters to the Editor The Journal of Thoracic and
Cardiovascular Surgery
October 1999
Table I. Laboratory results in the fall of 1998
Date of Valve size Age in Hematocrit LDH AST ALT 
Case operation (mm) 1998 Pregnancy (%) (U/L) (U/L) (U/L)
1 5/13/1985 27 52
2 5/14/1985 29 50 32 257 18 4
3 5/16/1985 27 43 34 194 14 8
4 3/19/1987 29 29 1 37 235 13 5
5 3/18/1987 25 21 44 323 36 10
6 3/23/1987 25 18 38 130 9 6
7 3/24/1987 31 26 4 38 264 18 5
8 3/26/1987 27 53 43 281 16 11
9 3/27/1987 27
10 4/14/1987 31 26 2 22 477 16 6
11 5/4/1987 31 33 39 421 32 10
12 6/19/1987 27 2
LDH, Lactic dehydrogenase; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Table II. Doppler echocardiographic assessment
MVA MVA PAsP PAsP TEE TEE 
LVd LVd LVEF LVEF LA LA (cm2) (cm2) (mm Hg) (mm Hg) PVL TVL 
Case (mm) (1) (mm) (2) (%) (1) (%) (2) (mm) (1) (mm) (2) (1) (2) (1) (2) (1) (1)
2 53 53 40 50 47 46 2.4 2.4 34 30 0 0
3 35 48 65 70 35 42 25 33 0 0
4 53 50 37 2.0 30 – 0 2+
5 51 48 55 67 42 46 2.7 2.6 23 34 0 2+
6 46 48 55 72 55 54 1.3 1.1 44 47 0 0
7 56 59 53 55 64 64 2.2 2.2 31 31 2+ 2+
8 41 50 65 60 48 51 3.1 3.0 – – 0 1+
10 61 62 35 66 48 50 2.2 2.0 43 33
11 52 56 55 64 49 53 2.4 2.4 27 – 0 2+
Investigations were performed in the summer of 1995 (1) and the fall of 1998 (2). LVd, Left ventricle at the end of diastole; LVEF, left ventricular ejection fraction;
LA, left atrium; MVA, mitral valve area. PAsP, pulmonary artery systolic pressure; TEE, transesophageal echocardiography; PVL, paravalvular leakage; TVL, trans-
valvular leakage.
ever, better to have all metal areas where the disc hits the
struts polished, as in all other patients (patients 4-12).
The area adjacent to the suture ring is the important place
to have a microporous surface to bind down the covering
from the suture ring. After 11 to 13 years of follow-up of 12
patients with the Björk-Shiley Monostrut mechanical mitral
valve with a microporous surface and without anticoagula-
tion, 9 children have been born and no thromboembolic com-
plications have been encountered.
Summary. This microporous surface will be covered in 3
months by a thin, smooth, glistening endothelium, free from
excrescence formation and fibrin precipitation, extending
over the groove and adjacent part of the suture ring. Thus the
thicker fibrous covering over the suture ring will be connect-
ed with the microporous covering. This will prevent a throm-
botic protrusion into the valve orifice with risk for emboli. As
the Monostrut valve has been accepted by the Food and Drug
Administration after 16 years of successful clinical use, the
results achieved from this pilot study indicate the necessity of
a multicenter study, the outcome of which could solve valve
surgery problems, especially for young girls.
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A fatal mechanical disorder of the TCI HeartMate
left ventricular assist system
To the Editor:
The HeartMate vented electric (VE) left ventricular assist
system (LVAS) (TCI; Thermo Cardiosystems Inc, Woburn,
Mass) has been used in more than 1400 patients worldwide and
in 42 patients in our hospital since November 1995. We expe-
rienced a case of fatal mechanical disorder with this device,
which required an emergency exchange of the LVAS. The
patient was a 34-year-old man who had undergone implanta-
tion of the HeartMate VE LVAS because of dilative cardiomy-
opathy more than 1 year earlier. He was referred to us twice for
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Fig 1. Clotted blood was seen in the whole LVAS motor chamber, which prevented the pump from working.
